免疫介导肿瘤治疗是对传统肿瘤学观念的重大革新,也是肿瘤治疗技术的又一突破。免疫介导肿瘤治疗药物在抑制肿瘤细胞生长的同时对正常人体细胞影响甚微,以nivolumab为代表的程序性死亡受体1(PD-1)及其配体程序性死亡配体1(PD-L1)为靶点的免疫治疗药物,具有较好的疗效和耐受性,日益受到关注。本文综述nivolumab治疗非小细胞肺癌的研究进展。 Immune-mediated tumor therapy is a major innovation in the concept of traditional oncology, cancer therapy is another breakthrough. Immune-mediated oncology drugs have little effect on normal human cells while inhibiting the growth of tumor cells. PD-1 and PD-1, represented by nivolumab, L1) as the target of immunotherapy drugs, with good efficacy and tolerability, more and more attention. This article reviews the research progress of nivolumab in the treatment of non-small cell lung cancer.